Zimmer Biomet (NYSE:ZBH) Given Hold Rating at Truist Financial

Truist Financial reissued their hold rating on shares of Zimmer Biomet (NYSE:ZBH) in a research note issued to investors on Wednesday, Marketbeat reports. Truist Financial currently has a $92.00 target price on the medical equipment provider’s stock, down from their previous target price of $98.00.

Several other equities analysts have also weighed in on ZBH. Citigroup reduced their price objective on shares of Zimmer Biomet from $98.00 to $95.00 and set a “neutral” rating for the company in a research report on Wednesday. William Blair started coverage on shares of Zimmer Biomet in a research report on Friday, February 20th. They set a “market perform” rating for the company. Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Sunday, April 19th. UBS Group restated a “sell” rating and set a $89.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Finally, Weiss Ratings upgraded shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $102.43.

Zimmer Biomet Stock Down 3.0%

Zimmer Biomet stock opened at $80.31 on Wednesday. The stock has a market cap of $15.54 billion, a price-to-earnings ratio of 22.69, a PEG ratio of 1.89 and a beta of 0.61. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. The company’s 50-day moving average price is $92.87 and its two-hundred day moving average price is $92.81. Zimmer Biomet has a 52 week low of $79.83 and a 52 week high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same quarter last year, the firm posted $1.81 EPS. The business’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, analysts expect that Zimmer Biomet will post 8.39 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is presently 27.12%.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 1.28% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ZBH. DV Equities LLC acquired a new position in shares of Zimmer Biomet in the fourth quarter worth about $25,000. Key Financial Inc boosted its holdings in shares of Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 163 shares during the period. Cullen Frost Bankers Inc. boosted its holdings in shares of Zimmer Biomet by 66.7% in the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 116 shares during the period. Monetary Solutions Ltd acquired a new position in shares of Zimmer Biomet in the fourth quarter worth about $30,000. Finally, Root Financial Partners LLC acquired a new position in shares of Zimmer Biomet in the third quarter worth about $31,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q1 results beat and guidance raised — Zimmer Biomet reported adjusted EPS of $2.09 (vs. $1.86 est.), revenue of ~$2.09B (beat) and organic sales growth; the company updated FY2026 adjusted EPS guidance to $8.40–8.55. These operational beats and the guidance raise are supportive for longer?term fundamentals. PR Newswire: Q1 Results
• Neutral Sentiment: Conference call / transcripts are available and highlight the company’s growth drivers and margin expansion; these give investors more detail on product momentum and the salesforce shift but have not calmed near?term volatility. Earnings Call Highlights
• Negative Sentiment: Finance leadership turnover — CFO Suketu Upadhyay departed and an interim CFO was named; reports link the exit to a sharp intraday selloff and said the stock plunged to multi?year lows on the news. Leadership uncertainty in the finance function is a clear near?term negative. CFO Transition (PR Newswire) Article: Stock Plunges
• Negative Sentiment: Analyst price?target cuts and mixed ratings — multiple firms trimmed targets (examples: JPMorgan $100?$95, Wells Fargo $98?$90, Stifel $110?$105, Truist trimmed its PT to $92) which lowers street support levels and can amplify selling pressure. Benzinga: Analyst Notes The Fly TickerReport
• Negative Sentiment: Technical / market context — the stock is trading with elevated volume, underperforming peers and around its 52?week low, increasing the likelihood of momentum-driven downside until leadership/catalysts stabilize. MarketWatch: Underperformance

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.